

K071125

## 510(k) SUMMARY of Safety and Effectiveness

### I. Applicant Information:

Date Prepared: 20 April 2007  
Submitter: AGA Medical Corporation  
Address: 5050 Nathan Lane North  
Plymouth, MN 55442  
Establishment  
Registration No. 2135147  
Contact Person: Jodi L. Raus, RAC  
Director of Regulatory Affairs  
Telephone Number: (763) 531-3065  
Fax Number: (763) 647-5932

JUN 18 2007

### II. Device Information:

Trade Name: AMPLATZER® Vascular Plug II  
Classification Name: Device, Embolization, Vascular  
Classification: Class II, 21 CFR 870.3300  
Product Code: KRD

Predicate Device: AMPLATZER® Vascular Plug  
510(k): K031810, Reg. No. 870.3300; Product Code: KRD

Predicate Device Intended Use: *The AMPLATZER® Vascular Plug is indicated for arterial and venous embolizations in the peripheral vasculature.*

Device Description: The AMPLATZER® Vascular Plug II is a sterile, single-use, triple-lobed, self-expanding Nitinol mesh occlusion device, with a screw-attachment for a Delivery Wire and radiopaque marker bands at both ends. The Plug is attached to a 135 cm Delivery Wire with a stainless steel screw. The AMPLATZER® Vascular Plug II is provided contained within a Loader Device that facilitates loading into a delivery catheter. The Delivery Wire is coiled and packaged in a hoop dispenser.

The AMPLATZER® Vascular Plug II is available in fully-expanded diameters of: 4mm, 6mm, 8mm, 10mm, 12mm, 14mm and 16 mm.

Intended Use: The AMPLATZER® Vascular Plug II is indicated for arterial and venous embolizations in the peripheral vasculature.

Comparison to  
Predicate Device:

The AMPLATZER® Vascular Plug II is substantially equivalent to the predicate device cleared by K031810. The two devices are both embolization devices with identical intended uses. Both devices have exactly the same patient-contacting materials, and have the same Nitinol Delivery Wire. Both devices come preloaded in a loader device. The two devices have the same operating principle, where a self-expanding Nitinol mesh device is received in a loader, delivered to the desired embolization site through a delivery catheter and, upon release, both devices expand to occlude the vessel or desired embolization site.

Three minor modifications were made to the AMPLATZER® Vascular Plug II:

1. Modification of the shape from a single-lobed to a triple-lobed design.
2. Use of multiple, thinner Nitinol wire braid layers (two or three), compared to the single braid layer of thicker wire in the original design.
3. Change to material used in outer layer of Loader component.

Test Data:

Verification and validation testing confirms that the functional characteristics of the AMPLATZER® Vascular Plug II are substantially equivalent to the predicate device cited. This included radial force testing, handoff and advancement forces, device deployment, recapture and detachment verification and overall strength determinations. Animal testing was also performed to validate the product under simulated conditions of use.

Summary:

Based on the technical information, intended use, laboratory verification tests and *in vitro* and *in vivo* performance information provided, the AMPLATZER® Vascular Plug II is substantially equivalent to the currently marketed predicate device.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

AGA Medical Corp.  
c/o Ms. Jodi Raus  
5050 Nathan Lane North  
Plymouth, MN 55442-3209

**JUN 18 2007**

Re: K071125  
Amplatzer Vascular Plug II  
Regulation Number: 21 CFR 870.3300  
Regulation Name: Vascular embolization device  
Regulatory Class: Class II  
Product Code: KRD  
Dated: May 30, 2007  
Received: May 31, 2007

Dear Ms. Raus:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Bram D. Zuckerman, M.D.  
Director  
Division of Cardiovascular Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K071125

Device Name: **AMPLATZER® Vascular Plug II**

Indications for Use:

**The AMPLATZER® Vascular Plug II is indicated for arterial and venous embolizations in the peripheral vasculature.**

Prescription Use X  
(Part 21 CFR 801 Subpart D)

AND/OR

Over-the-Counter Use \_\_\_\_\_  
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

*Anna R. V. Jones*  
(Division Sign-Off)  
Division of Cardiovascular Devices

510(k) Number K071125